Merck KGaA signs cancer and HIV deals in North America
This article was originally published in Scrip
Executive Summary
Merck KGaA has signed an agreement with the US–based biotherapeutics company Lpath to develop and commercialise Asonep, a Phase I monoclonal antibody for the treatment of various cancers.